路透9月1日 - Alumis公司 ALMS.O 周二表示,其一款试验性药物在针对一种名为系统性红斑狼疮的慢性自身免疫性疾病患者开展的中期临床试验中,未能达到主要目标。
路透9月1日 - Alumis公司 ALMS.O 周二表示,其一款试验性药物在针对一种名为系统性红斑狼疮的慢性自身免疫性疾病患者开展的中期临床试验中,未能达到主要目标。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.